Sonoma Pharmaceuticals Inc (NASDAQ:SNOA)’s traded shares stood at 3.38 million during the latest session, with the company’s beta value hitting 1.42. At the last check today, the stock’s price was $2.92, to imply an increase of 12.71% or $0.33 in intraday trading. The SNOA share’s 52-week high remains $9.37, putting it -220.89% down since that peak but still an impressive 13.7% since price per share fell to its 52-week low of $2.52. The company has a valuation of $3.91M, with an average of 0.17 million shares in intraday trading volume over the past 10 days and average of 339.74K shares over the past 3 months.
Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) trade information
After registering a 12.71% upside in the latest session, Sonoma Pharmaceuticals Inc (SNOA) has traded red over the past five days. The 5-day price performance for the stock is 4.63%, and 2.07% over 30 days. With these gigs, the year-to-date price performance is -19.09%. Short interest in Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) saw shorts transact 79898.0 shares and set a 0.22 days time to cover.
Sonoma Pharmaceuticals Inc (SNOA) estimates and forecasts
Looking at statistics comparing Sonoma Pharmaceuticals Inc share performance against respective industry, we note that the company has outperformed competitors. Sonoma Pharmaceuticals Inc (SNOA) shares are -28.80% down over the last 6 months, with its year-to-date growth rate higher than industry average at 47.37% against 16.60%. The rating firms project that company’s revenue will grow 21.48% compared to the previous financial year.
Revenue forecast for the current quarter as set by 1 analysts is 4.06M. Meanwhile, for the current quarter, a total of 1 analyst(s) estimate revenue growth to 4.44M.Earnings reports from the last fiscal year show that sales brought in 3.14M and 3.44M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 29.38% before jumping 29.11% in the following quarter.
SNOA Dividends
Sonoma Pharmaceuticals Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Sonoma Pharmaceuticals Inc (NASDAQ:SNOA)’s Major holders
Sonoma Pharmaceuticals Inc insiders hold 1.51% of total outstanding shares, with institutional holders owning 2.42% of the shares at 2.45% float percentage. In total, 2.42% institutions holds shares in the company, led by CITADEL ADVISORS LLC. As of 2024-06-30, the company held over 0.2 million shares (or 1.2504% of shares), all amounting to roughly $41412.0.
The next major institution holding the largest number of shares is GEODE CAPITAL MANAGEMENT, LLC with 86644.0 shares, or about 0.5551% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $18385.0.
We also have Fidelity Extended Market Index Fund and Fidelity Series Total Market Index Fund as the top two Mutual Funds with the largest holdings of the Sonoma Pharmaceuticals Inc (SNOA) shares. Going by data provided on Sep 30, 2024, Fidelity Extended Market Index Fund holds roughly 5.44 shares. This is just over 0.41% of the total shares, with a market valuation of $15621.0. Data from the same date shows that the other fund manager holds a little less at 1.26, or 0.09% of the shares, all valued at about 3619.0.
